ANGLE plc (GB:AGL) has released an update.
ANGLE plc’s recent study highlights the potential of dual CTC-DNA and ctDNA analysis in enhancing patient treatment strategies for non-small cell lung cancer. By using the Parsortix system, researchers identified genetic markers that could guide targeted therapies, potentially improving outcomes for patients resistant to existing treatments. This approach underscores ANGLE’s commitment to advancing precision medicine in oncology.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
